Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GXP-1 by Egret Therapeutics for Transplant Rejection: Likelihood of Approval
GXP-1 is under clinical development by Egret Therapeutics and currently in Phase I for Transplant Rejection. According to GlobalData, Phase...